Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Extra oxygen may boost exercise in lung disease patients

NCT ID NCT02551068

Symptom relief Sponsor: University of British Columbia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether breathing 60% oxygen during exercise helps people with idiopathic pulmonary fibrosis (IPF) who are taking nintedanib. 78 participants exercised on a bike or walked while getting either high oxygen or standard care. The goal was to see if they could exercise longer and feel less breathless after 8 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
60% oxygen
What this could lead to
If it works, this could point toward a simple way to help IPF patients exercise longer and feel less breathless.
What could go wrong
This is a small, completed study with 78 participants. The results may not apply to all IPF patients, and the benefit may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

78 people

The number who actually took part.

Start date

Dec 2015

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 19 years or older * Idiopathic Pulmonary Fibrosis (IPF) diagnosis according to American Thoracic Society and/or European Respiratory Society consensus criteria * Appropriate candidate for pulmonary rehabilitation * prescribed nintedanib by their treating physician or currently on nintedanib * 6 minute walk distance 50m or more * Oxygen saturation 92% or more by pulse oximetry at rest while breathing room air * Clinically stable for the preceding 6 weeks Exclusion Criteria: * Contraindication to treatment with nintedanib (based on Canadian labeling) * Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease) * Other significant extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and/or oxygenation * Forced vital capacity (FVC) less than 50% or Diffusion capacity for carbon monoxide (DLCO) less than 25% * Concurrent or recent participation (less than 6 months) in a pulmonary rehabilitation program * Use of prednisone greater than 10 mg/day for more than 2 weeks within 3 months of the first study visit * Use of pirfenidone within 4 weeks of screening * Significant emphysema (less than 10% volume on high resolution computed tomography (HRCT) or forced expiratory volume at one second (FEV1)/FVC less than 0.70)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic pulmonary fibrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Idiopathic pulmonary fibrosis

Contacts and locations

Locations

  • Laval University

    Québec, Quebec, G1V 0A6, Canada

  • McGill University

    Montreal, Quebec, H3A 0G4, Canada

  • McMaster University

    Hamilton, Ontario, L8S 4L8, Canada

  • Queens University

    Kingston, Ontario, K7L 3N6, Canada

  • St. Paul's Hospital

    Vancouver, British Columbia, V6Z1Y6, Canada

  • UBC Okanagan

    Kelowna, British Columbia, V1V 1V7, Canada

  • University of Alberta

    Edmonton, Alberta, T6G 2R3, Canada

  • University of Calgary

    Calgary, Alberta, T3M1M4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.